Quest Diagnostics is proud to be an executive partner of the 3rd Opioid Management Summit February 26-27, 2019 in Washington, DC.
Join us on February 26 at 10:30 AM as we present: Patterns of Drug Misuse in America and Reducing Risks…
In October 2018, the president signed the SUPPORT for Patients and Communities Act,which addresses multiple aspects of the opioid crisis. Several provisions in the bill are slated to increase access to medication-assisted treatment (MAT), in which buprenorphine or another medication is part of the treatment plan for substance…
Data released by the Centers for Disease Control and Prevention indicate that deaths due to drug overdoses climbed from 2015 through the end of 2017, but preliminary data suggest the annual death rate may have reached a plateau.
According to the data, total drug overdose deaths were approximately…
Diversion of prescription medications is a major part of the epidemic of substance abuse in the United States. Clinicians who prescribe opioids and other controlled substances have an important role to play in preventing drug diversion, through maintaining good records and secure prescription pads, communicating with patients and other prescribers,…
In late September 2018, the US House and Senate agreed on a compromise bill to address multiple aspects of the opioid crisis. Among the key provisions in the bill are ones to:
· Enhance access to non-opioid pain treatment options provided by Medicaid.
· Improve data sharing for…
How does oxycodone differ from hydrocodone? How powerful is fentanyl compared to morphine? A working knowledge of opioids is important for clinicians who treat patients with chronic pain. Opioids include:
Morphine, derived from secretions of the poppy plant. The strength of other opioids is usually given as “morphine equivalents,” based…
Where are the hotspots for drug misuse in America? And what are the trends in your state? Quest Diagnostics has produced an interactive map that provides state-by-state information that can guide your thinking on problems in your area.
The map details state-level data on test results that are…
For patients with chronic pain, opioid medications can offer an important treatment option. If you are a clinician who is new to prescribing opioids, there are several important resources and best practices that can help keep your patients safe and properly treated while receiving opioids.
Centers for Disease Control Guideline…
The Council of Economic Advisors says that the cost of the nation’s opioid epidemic in 2015 was $504 billion, or 2.8% of that year’s Gross Domestic Product. “This estimate dwarfs estimates from previous studies,” the Council states in its February 2018 CEA Annual Report. The Council is an…
The number of approved providers of buprenorphine per opioid overdose death is lower than average in 11 states in the Midwest and Mid-Atlantic, according to an analysis by the health policy consulting group Avalere. Buprenorphine is used to treat opiate use disorder, and may be prescribed by nurse practitioners and…
Drug Misuse in America 2018, a Quest Diagnostics Health Trends™ report, presents findings from analysis of more than 3.9 million de-identified aggregated clinical drug monitoring tests performed by Quest Diagnostics for patients in all 50 states and D.C. between 2011 and 2017. To our knowledge, this report is the largest…
Visit us at Booth 311 and get a sneak peek at our Health Trends™: Drug Misuse in America 2018 report
Health Trends™: Drug Misuse in America 2018, a Quest Diagnostics report, presents findings from analysis of more than 3.9 million de-identified aggregated clinical drug monitoring tests performed by Quest Diagnostics…
Chronic pain affects tens of millions of people in the United States, and according to the Centers for Disease Control, in 2016, prescribers wrote 66.5 opioid and 25.2 sedative prescriptions for every 100 Americans. “These are sobering statistics,” says F. Leland McClure, PhD, MSci., F-ABFT, director,…
Quest Diagnostics is pleased to sponsor the August 13-14, 2018 Opioid Management Congress in Nashville, TN. Use promo code: QUEST for an early registration discount, and join us for our lunch presentation on August 13, 2018:
Clinical Drug Monitoring & Analytics as an Objective…
Every state now has a prescription drug monitoring program (PDMP) in place to record prescriptions of controlled substances, but they vary widely in the information they collect and whether and how physicians must consult the database. Beginning in 2013, New York instituted mandatory consultation for physicians: before they prescribe an…
More than a quarter of patients being tested for either prescribed opioids or prescribed benzodiazepines tested positive for both drugs, according to a new study in the Journal of Addiction Medicine.
“Our findings far exceed previous estimates of combining opiates and benzodiazepines based on prescribing databases alone, suggesting existing prescription…
The quantity of opioids prescribed in the United States peaked in 2010 and has been falling since, according to a new study from the Centers for Disease Control and Prevention (CDC). But the quantity prescribed in 2015, the last year for which comprehensive data are available, is still more than…
It is clear that the prescription opioid epidemic is a nationwide problem, but for now, one of the most important weapons against it is being wielded inconsistently from state to state. Prescription Drug Monitoring Programs (PDMPs) are state-run electronic databases of prescribing and dispensing information from healthcare providers and pharmacies.…
The Federation of State Medical Boards (FSMB) recommends that urine drug testing be used as part of a comprehensive management strategy for patients receiving prescription opioids for chronic pain.
“Periodic and unannounced drug testing (including chromatography) are useful in monitoring adherence to the treatment plan, as well as in…
by Amanda J. Jenkins, Ph.D.
Scientific Director, Toxicology
Opioids and other medications (non-opioid analgesics, benzodiazepines, antidepressants, anticonvulsants, muscle relaxants) are prescribed to treat chronic pain of non-cancer origin.1
Ongoing monitoring of these patients is important to ensure safe and effective therapy. Drug testing is one tool utilized to identify…
For patients with chronic pain, opioids may offer important relief from suffering and help support activities of daily living. At the same time, if they are not used according to your prescription, opioids can do great harm. A prescription drug monitoring (PDM) program can help you maintain the maximum benefit…
Physicians must take into account many factors when making decisions about opioid prescriptions, including the risk that the individual patient may divert prescription medications for illegal use. To aid physician decision-making, the state of Maine in 2013 instituted its Diversion Alert program, a program that gives physicians access to…
In 2016, the Centers for Disease Control published an updated guideline for primary care clinicians who are prescribing opioids for chronic pain (outside of active cancer treatment, palliative care, and end-of-life care). It’s an extensive study, with a thorough review of the evidence. But the main message is contained in…